<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03321487</url>
  </required_header>
  <id_info>
    <org_study_id>ALSFUS001</org_study_id>
    <nct_id>NCT03321487</nct_id>
  </id_info>
  <brief_title>Blood-Brain Barrier Opening Using MR-Guided Focused Ultrasound in Patients With Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>Safety and Feasibility of Primary Motor Cortex Blood-Brain Barrier Opening Using Transcranial MR-Guided Focused Ultrasound With Intravenous Ultrasound Contrast Agent in Patients With Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and feasibility of&#xD;
      Blood-Brain Barrier (BBB) opening using transcranial MRI-guided focused ultrasound in&#xD;
      conjunction with an intravenous ultrasound contrast agent in patients with Amyotrophic&#xD;
      Lateral Sclerosis (ALS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 13, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Device and Procedure related adverse events</measure>
    <time_frame>At the time of the ExAblate MRgFUS procedure</time_frame>
    <description>The number and severity of device and BBB opening procedure related adverse events will be evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of contrast enhancement seen on post-procedure MRI</measure>
    <time_frame>At the time of the ExAblate MRgFUS procedure and 24 hours post-procedure</time_frame>
    <description>The extent and reversibility of BBB opening will be determined by the degree of contrast enhancement seen on post-procedure MRI with gadolinium-based contrast agent.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Stage I Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood-Brain Barrier opening with MRgFUS. BBB opening of a small volume of the primary motor cortex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage II Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood-Brain Barrier opening with MRgFUS. BBB opening of a larger volume of the primary motor cortex</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blood-Brain Barrier opening with MRgFUS</intervention_name>
    <description>ExAblate Transcranial MR-guided Focused Ultrasound to temporarily open the Blood-Brain Barrier</description>
    <arm_group_label>Stage I Cohort</arm_group_label>
    <arm_group_label>Stage II Cohort</arm_group_label>
    <other_name>Focused Ultrasound (FUS)</other_name>
    <other_name>Blood-Brain Barrier Disruption (BBBD)</other_name>
    <other_name>ExAblate MRgFUS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with laboratory supported probable, clinically probable or definite ALS&#xD;
             according to the World Federation of Neurology Revised El Escorial criteria (Brooks et&#xD;
             al. 2000).&#xD;
&#xD;
          2. Right-hand dominant male or female aged 18 years or older.&#xD;
&#xD;
          3. Capable of providing informed consent and complying with study procedures, including&#xD;
             tolerability in the supine position and MRI examination without significant&#xD;
             claustrophobia.&#xD;
&#xD;
          4. If taking riluzole, on a stable dose for at least 30 days prior to Screening Visit.&#xD;
&#xD;
          5. Slow Vital Capacity equal to or more than 50% predicted value for gender, height and&#xD;
             age in the 30 days prior to the Screening Visit and able to lie supine without BiPAP.&#xD;
&#xD;
          6. Severe left arm weakness and functional impairment, defined as Medical Research&#xD;
             Council muscle strength score equals 3 or less in the index finger abduction and thumb&#xD;
             abduction on the left side; OR severe left leg weakness and functional impairment,&#xD;
             defined as Medical Research Council muscle strength score equals 3 or less at the hip&#xD;
             flexors and ankle dorsiflexors on the left side.&#xD;
&#xD;
          7. Able to communicate during the ExAblate® MRI-guided FUS procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to complete high-density CT and MRI studies of the head at the Screening Visit&#xD;
             or any other MRI contraindication, such as:&#xD;
&#xD;
               -  Large body habitus and not fitting comfortably into the scanner&#xD;
&#xD;
               -  Difficulty lying supine and still for up to 3 hours in the MRI unit or&#xD;
                  significant claustrophobia&#xD;
&#xD;
          2. MRI findings:&#xD;
&#xD;
               -  Active infection/inflammation&#xD;
&#xD;
               -  Acute or chronic brain hemorrhages, specifically lobar or subcortical&#xD;
                  microbleeds, siderosis or macrohemorrhages&#xD;
&#xD;
               -  Tumor/space occupying lesion&#xD;
&#xD;
               -  Meningeal enhancement&#xD;
&#xD;
          3. More than 30% of the skull area traversed by the sonication pathway is covered by&#xD;
             scars, scalp disorders (e.g., eczema), or atrophy of the scalp.&#xD;
&#xD;
          4. Clips or other metallic implanted objects in the skull or the brain, except shunts.&#xD;
&#xD;
          5. Significant cardiac disease or unstable hemodynamic status including:&#xD;
&#xD;
               -  Documented myocardial infarction within six months of enrollment&#xD;
&#xD;
               -  Unstable angina on medication&#xD;
&#xD;
               -  Unstable or worsening congestive heart failure&#xD;
&#xD;
               -  Left ventricular ejection fraction below the lower limit of normal&#xD;
&#xD;
               -  History of a hemodynamically unstable cardiac arrhythmia&#xD;
&#xD;
               -  Cardiac or phrenic pacemaker&#xD;
&#xD;
               -  Known right-to-left, bidirectional, or transient right-to-left cardiac shunt&#xD;
&#xD;
               -  Patients with relative contraindications to perflutren including subjects with a&#xD;
                  family or personal history of QT prolongation or taking concomitant medications&#xD;
                  known to cause QTc prolongation,&#xD;
&#xD;
               -  QT prolongation observed on screening ECG (QTc &gt; 450 for men and &gt;470 for women)&#xD;
&#xD;
          6. Uncontrolled hypertension (systolic &gt; 150 or diastolic BP &gt; 100 on medication).&#xD;
&#xD;
          7. On medications that increase the bleeding risk, specifically: a) aspirin or another&#xD;
             antiplatelet medication (clopidogrel, prasugrel, ticlopidine, abciximab) for the last&#xD;
             7 days prior to treatment; b) oral, subcutaneous or intravenous anticoagulant&#xD;
             medications, such as oral vitamin K inhibitors for the last 7 days, non-vitamin K&#xD;
             inhibitor oral anticoagulant (dabigatran, apixaban, rivaroxaban) for the last 72&#xD;
             hours, and intravenous or subcutaneous heparin-derived compounds for the last 48&#xD;
             hours.&#xD;
&#xD;
          8. History of a bleeding disorder, coagulopathy or a history of spontaneous hemorrhage.&#xD;
&#xD;
          9. Known frontotemporal dementia.&#xD;
&#xD;
         10. Abnormal coagulation profile, specifically: platelet &lt;100,000/μl, Prothrombin Time &gt;14&#xD;
             seconds, activated partial thromboplastin time (aPTT) &gt;36 seconds, and INR &gt; 1.3.&#xD;
&#xD;
         11. Known cerebral or systemic vasculopathy, specifically cerebral amyloid angiopathy or&#xD;
             systemic or central nervous system vasculitis.&#xD;
&#xD;
         12. Known auto-immune condition with or without neurological manifestations (e.g.,&#xD;
             multiple sclerosis (MS), systemic lupus erythematous (SLE), Rheumatoid arthritis).&#xD;
&#xD;
         13. Current or planned use of oral, intramuscular or intravenous steroid drugs (such as&#xD;
             prednisone, prednisolone, dexamethasone, triamcinolone, methylprednisolone,&#xD;
             oxandrolone, and others) or immunosuppressant drugs (azathioprine, mycophenolate,&#xD;
             tacrolimus, sirolimus, cyclophosphamide, and others) for more than 7 days.&#xD;
&#xD;
         14. Known sensitivity/allergy to gadolinium (an alternative product may be used),&#xD;
             DEFINITY® contrast or any of its components.&#xD;
&#xD;
         15. Untreated, uncontrolled sleep apnea.&#xD;
&#xD;
         16. Impaired renal function with cystatin C-based estimated glomerular filtration rate &lt;30&#xD;
             mL/min/1.73m2 and acute renal injury.&#xD;
&#xD;
         17. Currently in a clinical trial involving an investigational product or non-approved use&#xD;
             of a drug or device.&#xD;
&#xD;
         18. Known respiratory diseases, specifically: chronic pulmonary disorders e.g.,&#xD;
             severe/uncontrolled COPD, pulmonary vasculitis, or other causes of reduced pulmonary&#xD;
             vascular cross-sectional area, asthma or hay fever.&#xD;
&#xD;
         19. Patients with a history of drug allergies or multiple allergies where the benefit/risk&#xD;
             of administering DEFINITY® is considered unfavorable by the study physicians in&#xD;
             relation to the product monograph for DEFINITY®.&#xD;
&#xD;
         20. Unqualified fit for the anesthesia by an anesthesiologist assessment, ASA I-III.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorne Zinman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Director, ALS/Neuromuscular Clinic, Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>October 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2017</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood-Brain Barrier disruption</keyword>
  <keyword>Blood-Brain Barrier opening</keyword>
  <keyword>magnetic resonance-guided focused ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

